H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer
David R. Spigel,John D. Hainsworth,Jitendra G. Gandhi,Victor G. Gian,James D. Peyton,Kimberly West-Osterfield,Bobby L. Clark,Elizabeth R. Vazquez,Suzanne F. Jones,Howard A. Burris,F. Anthony Greco +10 more
TL;DR: The ORR achieved with carboplatin and weekly topotecan was less than the anticipated rate of 70%; however, it was comparable with historical rates seen with other platinum doublets in the first-line extensive stage SCLC setting.
Posted ContentDOI
Association of Convalescent Plasma Treatment with Reduced Mortality and Improved Clinical Trajectory in Patients Hospitalized with COVID-19 in the Community Setting
Shanna A. Arnold Egloff,Angela Junglen,Joseph S.A. Restivo,Marjorie Wongskhauluang,Casey Martin,Pratik Doshi,Daniel Schlauch,Gregg Fromell,Lindsay E. Sears,Mick Correll,Howard A. Burris,Charles F. LeMaistre +11 more
TL;DR: In this article, the authors performed a comparative effectiveness study of convalescent plasma (CP) for all-cause, in-hospital mortality in patients with COVID-19.
Journal ArticleDOI
A Phase I trial of protracted oral fixed-dose temozolomide.
Suzanne F. Jones,F. Anthony Greco,Victor G. Gian,Fernando T. Miranda,Eric L. Raefsky,John D. Hainsworth,Noel T. Willcutt,Aurelia F. Beschorner,Glyndon Kennerly,Howard A. Burris +9 more
TL;DR: The current Phase I trial was conducted to determine the dose‐limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed‐dose temozolomide when administered for 5 of every 7 days on a continuous basis.
Journal ArticleDOI
Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.
Todd M. Bauer,Jeffrey R. Infante,Ramesh K. Ramanathan,Glen J. Weiss,Jasgit C. Sachdev,Howard A. Burris,James M Hinson,Everardus Otto Orlemans +7 more
TL;DR: Two phase 1, open-label, 3 + 3 dose-escalation studies evaluated SNX-5422 when given daily (QD) or every-other-day (QOD) during the first 30 days of treatment in patients with advanced solid tumors or lymphoma.
Proceedings ArticleDOI
Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors
Philippe L. Bedard,Juneko E. Grilley-Olson,Mark Cornfeld,Leanne Cartee,Susan Warwick,Albiruni R. Razak,Lee-Anne Stayner,Yuehui Wu,Rebecca Greenwood,Veronica Viana-Gilmartin,Carrie B. Lee,Johanna C. Bendell,Howard A. Burris,Luca Gianni,Cristiana Sessa,Jeffrey R. Infante,Angelica Fasolo +16 more
TL;DR: Tolerability of the combination was limited by rash, GI toxicity, fatigue and anorexia, and a recommended phase 2 dose and schedule was not defined despite exploring alternative schedules including twice daily and intermittent dosing of GSK458.